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Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising
strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated
breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic
settings for the treatment of ovarian, BRCA-mutated breast, and other cancers. We herein review the development of
PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in
combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics.
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Modern strategies for the development of novel cancer
therapies include agents targeting specific molecular de-
fects that characterize certain cancer cells in order to in-
crease treatment efficacy and reduce toxicities. In breast
cancer, targeted therapies have long been effective, as
agents targeting hormone receptors in tumors express-
ing them and as antibodies or tyrosine kinase inhibitors
targeting overexpressed or amplified HER2 molecules.
Breast tumors expressing none of these are called triple-
negative breast cancers (TNBC), which comprise about
15 % of breast cancers overall, about 70 % of breast can-
cers in individuals harboring a germline BRCA1 muta-
tion, and 20 % in BRCA2 mutation carriers [1–4]. The
discovery of the family of nuclear enzymes poly(ADP-ri-
bose) polymerases (PARPs) and their role in DNA-
damage repair pathways opened the possibility of
developing a new class of antineoplastic drugs with the
ability to interfere with the DNA damage repair systems of
cancer cells – PARP inhibitors (PARPi). One characteristic
of BRCA-mutated cancers is defective function of one of
the major DNA damage repair pathways, the homologous
recombination (HR) pathway. The original concept of the
activity of PARP inhibitors was that they acted through
synthetic lethality by targeting the base excision repair
pathway (BER); in tumor cells with defects in a different* Correspondence: judy_garber@dfci.harvard.edu
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to cell death. The preferential sensitivity of BRCA-
associated breast and ovarian cancers was therefore pre-
dicted as the tumor cells are characterized by defective
homologous recombination repair. Subsequently, PARPi
have shown significant activity in BRCA-associated breast,
ovarian, and other cancers [5, 6]. However, the activity in
sporadic ovarian cancers suggests a more complex mech-
anism of action described below [7].PARPs and DNA damage repair
PARPs are a family of enzymes involved in various activ-
ities in response to DNA damage [8]. Eighteen compo-
nents of this family have been discovered; PARP-1 to -3
are so far the only members defined as DNA damage-
dependent PARPs [9].
PARP activation, largely driven by DNA damage (other
mechanisms may occur, as reviewed by Bürkle et al.
[10]), determines post-transcriptional modification of
nuclear proteins such as histones [9]. PARP-1 activation
is one of the earliest responses to DNA damage in hu-
man cells [11, 12]. The ADP-ribosylation of histones and
the recruitment of chromatin remodeling enzymes cre-
ate a relaxed chromatin state that is appropriate for
DNA repairing activities (Fig. 1a). The ADP-ribose poly-
mer synthesized by PARP acts as a “flag” that drives the
assembly of DNA-repair complex at sites of DNA dam-
age, mainly promoting BER and single strand break re-
pair (SSBR) pathways [9], while involvement of PARPs inhis article is distributed under the terms of the Creative Commons
creativecommons.org/licenses/by/4.0), which permits unrestricted use,
um, provided you give appropriate credit to the original author(s) and the
ons license, and indicate if changes were made. The Creative Commons
eativecommons.org/publicdomain/zero/1.0/) applies to the data made
ted.
Fig. 1 Current model for PARP role in DNA damage repair and PARP inhibition – BRCA mutation synthetic lethality. a When single-strand break
(SSB) is detected, PARP recruitment and activation leads to SSB repair through poly(ADP-ribosyl)ation (PARylation) of histones and chromatin remodeling
enzymes, auto-PARylation of PARP, and recruitment of PARP-dependent DNA repair proteins. Repaired DNA can undergo replication determining cell
survival. b In the presence of PARP inhibitors, PARPs recruited to DNA-damage sites are no longer able to activate PARP-dependent repair systems and to
dissociate from DNA (due to catalytic activity inhibition and/or direct trapping), determining replication fork (RF) stalling during DNA replication. Stalled
RF eventually collapse creating double strand break (DSB). DSB can be repaired by homologous recombination (HR) and replication may restart, leading
to cell survival. In BRCA-deficient cells, HR is impaired, thus DSB cannot be efficiently repaired; in this context, DSB accumulate determining cell death
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repair system) is likely limited [13].Rationale for development of PARPi in breast cancer
Since cancer is a disease in which DNA replication is crit-
ical, replication errors are prominent, and deficiencies in
DNA-repair pathways are common [14], the involvement
of PARPs in DNA-repair pathways stimulated the devel-
opment of agents capable of targeting PARP activity.
To maintain DNA integrity, HR-deficient cells rely on
secondary DNA repair pathways, such as BER, SSBR,
and non-homologous end joining. When PARP-
dependent activation of BER/SSBR and non-homologous
end joining is defective, cells rely on the HR pathway to
restore DNA integrity. BRCA1 and BRCA2 proteins are
key actors of the HR apparatus and deficiency of either
(secondary to germline mutation in one copy and loss of
heterozygosity inactivating or removing the other copy)
results in inefficient activation of HR (Fig. 1b). Using
BRCA1- and BRCA2-deficient cell lines and mouse xe-
nografts, Bryant et al. [15] and Farmer et al. [16] demon-
strated marked in vitro and in vivo cytotoxicity of PARPimonotherapy in tumor cells with intrinsic HR deficiency,
with close to no effect on BRCA-proficient cells.
The model explaining this “synthetic lethality” effect of
PARP inhibition in HR-deficient cells is comprehensively
reviewed by Helleday [17]. Briefly, suppression of PARP
catalytic activity blocks the formation of ADP-ribose poly-
mers at site of SSB, hence PARP-dependent DNA-damage
repair complexes cannot be efficiently recruited. Unre-
paired SSB eventually lead to stalling of replication forks
[17]. Stalled replication forks collapse into double strand
breaks that are highly cytotoxic lesions if not repaired by
HR [17], the repair mechanism inefficiently activated in
BRCA-mutated cancers. Recent data suggest that another
mechanism of action of PARPi, so-called “PARP trapping”,
is more important in determining PARPi cytotoxicity.
Murai et al. [18] showed that PARPi prevent dissociation
of recruited PARPs from DNA-damage sites: these stabi-
lized PARP/DNA complexes determine stalling of the rep-
lication fork during DNA replication, with subsequent
formation of double strand breaks.
The observation that BRCA-mutated breast cancers show
an impairment in HR pathways [19], and that some spor-
adic TNBC are phenocopies of BRCA1-mutated cancers
Livraghi and Garber BMC Medicine  (2015) 13:188 Page 3 of 16(i.e. they display a phenotype resembling BRCA1-mutated
cancers without harboring a BRCA1 mutation, a feature
also defined as “BRCAness”, see below) [20, 21], led to ex-
ploration of the application of PARP inhibition to the treat-
ment of breast cancer (BRCA-associated and TNBC).
Clinical application in breast cancer
Clinical development of PARPi started in 2003 and fo-
cused on two strategies: utilizing PARPi in combination
with other drugs in a range of solid malignancies or using
PARPi monotherapy in specific cancer types with features
(like impairment of DNA-damage repair systems alterna-
tive to the PARP-dependent ones) that would be predicted
to be highly sensitive to PARP inhibition. Testing of
PARPi in combination with cytotoxic drugs showed the
feasibility of this approach with overall good tolerability,
but there was little evidence of activity in unselected
patients [22]. In contrast, promising data emerged in
the treatment of patients with breast and ovarian cancers
[23, 24], the two malignancies most frequently associated
with BRCA mutations.
Clinical testing of PARPi was initially slowed by nega-
tive results from a phase 3 trial of iniparib, a compound
inaccurately classified as a PARPi [25]. Subsequently, it
was shown that iniparib and its metabolites do not in-
hibit PARP in intact cells [26], and clinical development
of genuine PARPi gained new vigor. Currently, five com-
pounds with the ability to inhibit the activity of various
PARPs are being investigated in clinical trials (Table 1).
Below, we will present the most important findings from
phase 1 and 2 clinical trials evaluating the efficacy of
PARPi in the treatment of breast cancer. These data are
also summarized in Tables 2 and 3.Table 1 PARPi compounds in clinical development
Drug name Pharmaceutical company
Olaparib (AZD2281) AstraZeneca
Veliparib (ABT-888) Abbvie
Niraparib (formerly MK-4827) Tesaro
Talazoparib (BMN-673) BioMarin Pharmaceuticals
Rucaparib (formerly AG-14699) Clovis Oncology
CEP-9722 Teva Pharmaceutical Industries
BRCAm, BRCA1/2 mutation-associatedClinical trials in advanced disease
PARPi as single agent therapy
Following the demonstration by Bryant and Farmer
[15, 16] of the cytotoxic effect of PARP inhibition in
HR-deficient cells, there was interest in studying the activ-
ity of PARPi as monotherapy in solid tumors. In earlier
studies, the population enrolled in these trials was not re-
stricted to patients with known BRCA mutations, but
encompassed also those whose cancer displayed a pheno-
type similar to BRCA-mutated cancers. Clinically, this
group included triple-negative breast cancers and high-
grade serous or poorly differentiated ovarian cancer. The
term “BRCAness” was introduced to identify sporadic tu-
mors that shared common phenotypic features with famil-
ial BRCA tumors [20]. Attempts to identify cancers with
BRCAness included evaluation of epigenetic silencing of
BRCA genes [27], measurement of levels of proteins in-
volved in HR [28], and of foci of DNA-repair proteins like
gammaH2AX [5, 29]. However, after preliminary data
showing minimal efficacy of PARPi in sporadic breast can-
cers, some of the trials were amended to enrich the study
cohorts for BRCA-associated tumors [5, 30].
Initial phase 1 testing of olaparib as monotherapy in
BRCA-associated breast and ovarian cancers showed en-
couraging results: 47 % of patients with BRCA-associated
breast, ovarian, or prostate cancers treated with olaparib
achieved a partial response, and 63 % of them derived clin-
ical benefit (tumor marker decrease or radiologic response
or stable disease for 4 or more months) [5]. A phase 1
study of niraparib in patients with advanced solid tumors
enriched for BRCA-associated cancers reported an overall
response rate of 40 % (8 of 20) in patients with BRCA-
associated ovarian cancer and 50 % (2 of 4) in patients withCurrent investigational phase in breast cancer
Phase 3 studies in adjuvant and advanced settings in germline
BRCAm breast cancer
Phase 3 study in neoadjuvant setting in combination with carboplatin
and standard therapy in triple-negative breast cancer
Phase 2/3 studies in advanced setting as combination therapy in
germline BRCAm breast cancer
Phase 3 study in advanced setting in germline BRCAm breast cancer
Phase 3 study in advanced setting in germline BRCAm breast cancer
Phase 2 studies in advanced setting in BRCAm breast cancer
Phase 2 study in advanced setting in germline BRCA intact breast cancer
Phase 2 study in neoadjuvant setting in BRCAm breast cancer
Phase 2 study in advanced setting in patients with known germline
BRCAm solid tumors
Phase 2 study in adjuvant setting in triple-negative breast cancer or
germline BRCAm breast cancer
Phase 2 study in advanced setting in solid tumors
Table 2 Phase 1/2 studies of PARPi monotherapy in metastatic breast cancers, with spotlight on BRCA mutated patients
Study Name
(NCT)
Ref. Phase Tumor type No. of
patients




NCT00516373 [5] 1 Solid tumors 60/9 (3) Olaparib (10–600 mg bid) PK, PD, safety
and tolerability
ORR: 15 % ORR 33 % One CR in BRCAm
BC lasting more than
60 weeks
NCT00572364 [119] 1 Solid tumors 12/4 (NK) Olaparib (100–400 mg bid) Safety and
tolerability
ORR: 8 % – One patient with BC and
family history of BC had
PR for 13 months
NCT00494234 [34] 2 BRCAm BC 54/54 (54) C1: olaparib (400 mg bid) ORR – ORR C1: 41 %
C2: olaparib (100 mg bid) ORR C2: 22 %
NCT00679783 [7] 2 TNBC or BRCAm BC,
HGSOC or BRCAm OC
90/26 (10) Olaparib (400 mg bid) ORR ORR in BC: 0 % ORR: 0 % Evidence of activity in
non-BRCAm OC and
platinum-resistant OCORR in OC: 29 % 50 % of unconfirmed
PR (by RECIST)
NCT01078662 [6] 2 BRCAm solid tumors 317/62 (62) Olaparib (400 mg bid) ORR ORR: 26 % ORR: 13 % Mean number of previous
regimens for advanced
disease: 4.6DS ≥8 weeks: 47 %
Veliparib
NCT00892736 [120] 1 TNBC, HGSOC and
BRCAm BC and OC
98/35 (14) Veliparib (50–500 mg) Tolerability ORR in BRCAm: 24 % ORR: 29 %
ORR in BRCA wt: 4 % CBR: 57 %
Talazoparib
NCT01286987 [32] 1 Solid tumors 39/8 (6) Talazoparib (25–1100 μg) PK, PD, safety and
anti-tumor activity
ORR: 65 % in BRCAm OC ORR: 33 %
Niraparib
NCT00749502 [31] 1 Solid tumors 100/12 (4) Niraparib (30–400 mg) Safety and
tolerability
ORR: 18 % in overall




NCT01482715 [33, 121] 1–2 BRCAm BC and OC 56/27 (27) Rucaparib (18 mg/m2) ORR Data mixed between
OC and BC, at RP2D
ORR: 80 % (4/5)
–
BC Breast cancer, BID bis in die, BRCAm BRCA1/2 mutation-associated, CBR Clinical benefit rate; CR Complete response, DS Disease stabilization, HGSOC High-grade serous ovarian cancer, NK Not known, OC Ovarian
cancer, ORR Objective response rate, PD Pharmacodynamics, PK Pharmacokinetics, RP2D Recommended phase 2 dose, TNBC Triple-negative breast cancer, WT Wild type













Table 3 Phase 1/2 studies of PARPi as combination therapy in metastatic breast cancers, with spotlight on BRCA mutated patients
Study name
(NCT)






NCT00707707 [122] 1 TNBC 19/19 (NK) Olaparib (200 mg bid) +
PTX (90 mg/m2)
Safety and tolerability ORR: 37 % – First- or second-
line treatment
only
NCT00710268 [79] 1 Solid tumors 12/3 (NK) Olaparib (100–400 mg bid) +
BEV (10 mg/kg)
Safety and tolerability No data on response
reported
– No grade 3 or
4 hematologic
toxicities
NCT00782574 [23] 1 BC, OC, peritoneal
cancer, pancreatic cancer
54/42 (17) Olaparib (50–200 mg bid
continuously vs. intermittent) +
CDDP (75 mg/m2)






NCT01116648 [45] 1 TNBC, OC 28/8 (3) Olaparib (100–400 mg bid) +
cediranib (20–30 mg)
Safety and tolerability Overall ORR: 29 % ORR: 0 %
BC ORR: 0 %
BC CBR: 29 %
NCT01445418 [123] 1 BRCAm OC and BC 45/8 (8) Olaparib (100–400 mg bid) +
CBDCA (AUC 3–5)
Safety and tolerability ORR: 52 % ORR: 88 % One CR in
BRCAm
BC for 3 months
Veliparib
NCT00535119 [124] 1 Solid tumors 68/14 (NK) Veliparib (20–120 mg) + CBDCA
(AUC 5–6) + PTX (150–200 mg/m2)
PK, safety and tolerability ORR: 19 % – One CR in BC
NCT00740805 [125] 1 Solid and hematologic tumors 18/14 (5) Veliparib (50–150 mg) + DOX
(60 mg/m2) + CYC (600 mg/m2)
Tolerability No overall
results reported
ORR: 60 % Expansion
cohort study
in BC ongoing
NCT01063816 [126] 1 Solid tumors 59/10 (NK) Veliparib (250 mg bid) + CBDCA
(AUC 4) + GEM (800 mg/m2)
PK, safety and tolerability ORR: 22 % –
NCT01104259 [53] 1 TNBC or BRCAm BC 45/45 (12) Veliparib (20–300 mg) + CDDP
(75 mg/m2) + VNR (25 mg/m2)
Tolerability ORR: 55 % ORR: 73 %
NCT01251874 [127] 1 BC 44/44 (16) Veliparib (50–200 mg) + CBDCA
(AUC 5–6)
Safety and tolerability ORR: 19 % ORR: 25 %
NCT01445522 [128] 1 Solid tumors and lymphomas 35/12 (NK) Veliparib (20–80 mg) + CYC (50 mg) Safety and tolerability ORR: 20 % –
Not reported [54] 1 BRCAm BC 26/26 (26) Veliparib (50–200 mg) + CBDCA
(AUC 5–6)
Safety and tolerability – ORR: 46 %
CBF: 74 %
NCT01281150 [55] 1 Solid tumors 30/24 (5) Veliparib (50–200 mg) + PTX
(80 mg/m2) + CBDCA (AUC 5–6)















Table 3 Phase 1/2 studies of PARPi as combination therapy in metastatic breast cancers, with spotlight on BRCA mutated patients (Continued)
NCT01009788 [52] 2 BC 41/41 (8) Veliparib (40 mg bid) +
TMZ (150 mg/m2)






15 %, CBR: 45 %
CBF: 63 %
Rucaparib
NCT01009190 [129] 1 Solid tumors 23/5 (NK) Rucaparib (80–360 mg) +
CBDCA (AUC 3–5)
Safety and tolerability DCR: 50 % –
CEP-9722
NCT00920595 [130] 1 Solid tumors 26/7 (NK) CEP-9722 (150–1000 mg) +
TMZ (150 mg/m2)
PK, PD, safety and
anti-tumor activity
ORR: 5 % –
BC Breast cancer, BEV Bevacizumab, BID bis in die, BRCAm BRCA1/2 mutation-associated, CBDCA Carboplatin, CBR Clinical benefit rate, CDDP Cisplatin, CR Complete response, CYC Cyclophosphamide, DCR Disease control rate,
DOX Doxorubicin, DS Disease stabilization, GEM Gemcitabine, HGSOC High-grade serous ovarian cancer, NK Not known, OC Ovarian cancer, ORR Objective response rate, PD Pharmacodynamics, PK Pharmacokinetics,
PTX Paclitaxel, RP2D Recommended phase 2 dose, TMZ Temozolomide, TNBC Triple-negative breast cancer, VNR Vinorelbine, WT Wild type
Clinical benefit: CR + PR + SD for ≥24 weeks
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therapy has shown antitumor activity in patients with
BRCA mutations, with an objective response rate of 65 %
in ovarian and peritoneal tumors and 33 % (2 of 6 patients)
in breast cancers [32]. Data presented at ASCO 2014 on
single agent rucaparib showed efficacy in BRCA-associated
ovarian, breast, and pancreatic cancers [33].
These data from phase 1 trials guided the development
of phase 2 studies in the population of patients with
BRCA-associated cancers or with cancer usually associ-
ated with “BRCAness”, namely triple-negative breast
cancer and high-grade serous ovarian cancer (HGSOC).
Tutt et al. [34] reported efficacy of olaparib as mono-
therapy in 54 patients with advanced breast cancer and
germline BRCA1/2 mutations. At the maximum tolerated
olaparib dose of 400 mg bid, a 41 % objective response
rate was observed, with responses in both TNBC and hor-
mone receptor-positive HER2-negative patients. Toxicities
were generally manageable, with treatment-related adverse
events reported in 81 % of patients, but grade 3 or 4
events occurred in only 24 % of patients. Efficacy data
from this study compare favorably with response rates in
studies of single agent cytotoxics (capecitabine [35], vino-
relbine [36], eribulin [37], ixabepilone [38–40]) and of
new anti-HER2 targeted therapies (pertuzumab [41] and
T-DM1 [42]) in advanced breast cancer treatment. Similar
results from a parallel phase 2 study of olaparib mono-
therapy in recurrent ovarian, fallopian tube, or peritoneal
cancers were reported by Audeh et al. In germline
BRCA1/2 mutation-positive patients, the objective re-
sponse rate was 33 % [43]. It should be noted that in both
trials, for the first time, a documented germline BRCA
mutation was an enrollment criterion [34, 43].
Gelmon et al. [7] assessed safety and efficacy of olaparib
as a single agent in HGSOC and TNBC in an important
trial that also demonstrated the feasibility of pre- and
post-treatment biopsies. While sustained responses were
documented in HGSOC, no confirmed objective response
was shown in TNBC, regardless of BRCA-mutation status,
although 50 % of BRCA-mutation carriers had a greater
than 30 % reduction in the target lesion. The authors spec-
ulated that the lack of evidence of efficacy in BRCA-
associated breast cancers in this trial could be due to
chance because of small sample size or population charac-
teristics (heavily pretreated patients) [7].
Kaufman et al. [6] reported data of a phase 2 study
(NCT01078662) of olaparib monotherapy in 298 pa-
tients with diverse recurrent cancers (mostly ovarian,
breast, pancreatic, and prostate) and confirmed BRCA1/2
mutations (a study design called “basket trial”). Breast can-
cer tumor response rate was 12.9 % in 62 patients, and 47
% of patients had disease stabilization for ≥8 weeks. The
lower objective response rate in this study compared with
previous studies [5, 34] could be due to the fact that thestudy population was more heavily pretreated than in
other trials (mean of 4.6 prior chemotherapy regimens in
the metastatic setting vs. 3 in Tutt et al. [6]).
When tested in ovarian cancer, PARPi showed efficacy
regardless of BRCA status. In the previously cited Gelmon
et al. [7] study, olaparib induced sustained responses in
non-BRCA mutant HGSOC. Responses to olaparib were
also observed in ovarian cancer patients with wild type or
unknown BRCA status in a study of maintenance therapy
after platinum-based chemotherapy [44] and in a study of
olaparib plus cediranib [45]. Molecular studies suggested
that up to 20 % of HGSOC lose BRCA1 or BRCA2 func-
tion through epigenetic events [46], thus expressing an
HR-deficient phenotype with sensitivity to PARPi even in
the absence of somatic/germline BRCA mutation.
Studies of veliparib monotherapy in metastatic breast
cancer are currently in progress [47, 48]; data on veli-
parib efficacy as single agent in gynecological cancers
are already available. Coleman et al. [49] reported data
from a multicenter phase 2 study in BRCA-associated
persistent or recurrent ovarian, fallopian tube, or pri-
mary peritoneal cancer: objective response rate to single
agent veliparib was 26 % and progression-free survival at
6 months was 54 %, without significant difference be-
tween platinum-sensitive or platinum-resistant tumors.
PARPi in combination therapy
PARPi have been tested in the treatment of metastatic
breast cancer in combination with multiple compounds
in phase 1 and 2 studies [22]. Preclinical data showed
that veliparib exerts remarkable synergic activity with
other cytotoxic compounds [50]: in particular, veliparib
enhanced temozolomide’s cytotoxic effect even in
tumor types not typically responsive to temozolomide
[51] with a good safety profile. Veliparib has been fur-
ther clinically explored mainly as a part of combination
therapy. In a phase 2 trial in BRCA-associated breast
cancers, treatment with veliparib and temozolomide of-
fered a response rate of 22 % and a clinical benefit rate
of 50 % (defined as complete response, partial response,
or stable disease) [52]. Efficacy was successively con-
firmed in a larger expansion cohort with patients previ-
ously treated with platinum compounds or PARPi [30].
Other combinations between PARPi and chemotherapy
drugs have been proven effective in early clinical trials: the
best results in terms of efficacy emerged from combination
with cisplatin [23, 53] and carboplatin [54, 55], as well as
topotecan [56], with response rates in BRCA-related breast
cancers up to 73 % [23, 53]. Contrasting data about the
safety of the combination therapy approach emerged from
these studies. The combination topotecan-olaparib showed
dose-limiting hematological adverse events at sub-
therapeutic doses of olaparib [57]; in contrast, veliparib
combinations have been better tolerated overall.
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companion for a PARPi, and studies show that different
PARPi may combine more or less efficiently with cytotoxic
drugs with different mechanisms of action [58, 59]. The
differences in synergistic effect between cytotoxic drugs
and PARPi may be explained by PARPi mechanisms of ac-
tion. Indeed, some PARPi exert their cytotoxic effect
mainly suppressing PARPs’ catalytic activity (veliparib),
while others more by trapping PARPs to DNA (olaparib,
talazoparib, rucaparib, niraparib) [18]. It has been pro-
posed that PARP trapping is synergistic with alkylating
agents, while PARP catalytic inhibition synergizes with
topoisomerase I inhibitors [58]. In preclinical models, pro-
liferation of breast cancer cells is more potently sup-
pressed when both mechanisms of PARP inhibition are
present [18]. On the other hand, the higher toxicity of this
class of PARPi may render them more toxic in combin-
ation with cytotoxic therapies.
Ongoing studies in the metastatic setting
Ongoing randomized phase 3 studies of PARPi in meta-
static breast cancer are limited to patients with docu-
mented BRCA1/2 mutations (Table 4). Three parallel
study designs will test oral PARPi monotherapy vs. physi-
cian’s choice single agent chemotherapy in breast cancer
patients with PARPi-naive metastatic disease with germline
BRCA1/2 mutations: BRAVO (niraparib, NCT01905592
[60]), EMBRACA (talazoparib, NCT01945775 [61]), and
OlympiAD (olaparib, NCT02000622 [62]). Finally, study
NCT02163694 [63] will test the efficacy of veliparib versus
placebo in combination with carboplatin and paclitaxel in
HER2-negative metastatic or locally advanced, unresect-
able, BRCA-associated breast cancer.
Results from these studies are eagerly awaited and, if
positive, will form the basis of applications for Food
and Drugs Administration approval of PARPi for the
treatment of metastatic BRCA-associated breast cancer.
Approval will require an acceptable safety profile (see
below) in a well-characterized and defined target popu-
lation that currently lacks a specific targeted therapy. In
2014, both the European Medicines Agency and the
Food and Drugs Administration [64, 65] granted accel-
erated approval to olaparib in high-grade serous ovar-
ian, fallopian tube, and primary peritoneal cancer based
on the results of two phase 2 trials [44, 66].
Going beyond the metastatic setting
Conventionally, new antineoplastic drugs are tested as
adjuvant treatments for breast cancer after solid data
from phase 3 trials in the metastatic setting become
available. In the case of PARPi, the remarkable activity
of olaparib and veliparib in multiple phase 2 trials and
their manageable toxicity profiles have led to trials of
several PARPi in the adjuvant and neoadjuvant settings(Table 4). The adjuvant trial OlympiA is evaluating 1
year of the PARPi olaparib [67]. Data for the acceptability
of olaparib given for extended periods of time come from
a phase 2 study of single agent olaparib as maintenance
therapy in platinum-sensitive ovarian cancer – median
duration of treatment 206 days – but some patients stayed
on the medication for years [44].
The OlympiA trial (NCT02032823 [68]) will assess the
efficacy and safety of up to 12 months of olaparib versus
placebo as adjuvant treatment in patients with germline
BRCA1/2 mutations and high-risk hormone receptor-
negative HER2-negative primary breast cancer who have
completed definitive local treatment and neoadjuvant or
adjuvant chemotherapy. Eligibility criteria have recently
been expanded to allow for enrollment of high-risk hor-
mone receptor-positive patients. Randomization will be
stratified by prior neoadjuvant versus adjuvant chemother-
apy, and according to the use of prior platinum-based
chemotherapy for breast cancer. The post-neoadjuvant
treatment group will comprise patients in whom patho-
logic complete response was not achieved following at
least six cycles of neo-adjuvant chemotherapy. The pri-
mary end point will be interval disease-free survival, and
the secondary end points will be overall survival, distant
disease-free survival, and the development of new primary
invasive cancers.
Rucaparib is being tested in a phase 2 trial as adjuvant
treatment for TNBC or BRCA-mutated HER2-negative
breast cancers with residual disease after preoperative
chemotherapy (NCT01074970) [69]; preliminary data pre-
sented at ASCO 2014 showed no improvement in 1-year
disease-free survival with rucaparib plus cisplatin versus cis-
platin alone in the intent-to-treat population; rucaparib did
not add substantial toxicity to the cisplatin treatment [70].
The I-SPY2 study assesses sequential novel agents in
the neoadjuvant treatment of breast cancer. In the I-
SPY-2 trial assessing the addition of veliparib and carbo-
platin to standard neoadjuvant therapy in TNBC, an
estimated 52 % pathologic complete response rate was ob-
served in the experimental arm versus 26 % in the stand-
ard treatment arm [71]. In the cooperative group
neoadjuvant trials GeparSixto and Alliance 40603, the
addition of carboplatin to standard neoadjuvant chemo-
therapy increased pathological complete response rates in
TNBC from 42.7 % to 53.2 % and from 41 % to 54 %, re-
spectively [72, 73]. In GeparSixto, this effect is most evi-
dent in patients with germline BRCA1/2 or RAD51
mutations (the pathological complete response rate with
carboplatin was 66.7 % versus 43.5 % without carboplatin).
Participants are currently being accrued to a randomized
three arms phase 3 trial that will test the efficacy of the
addition of carboplatin plus veliparib, carboplatin alone, or
placebo to standard neoadjuvant chemotherapy (Brightness
Study – NCT02032277) [74].
Table 4 Ongoing and recruiting phase 2/3 studies
Study name (NCT) Ref. Phase Setting Investigational arm(s) Comparator arm(s) Primary endpoint Study status
Olaparib
OlympiAD [62] 3 ADV Olaparib monotherapy Physician’s choice CT PFS R
(NCT02000622)
OlympiA [68] 3 ADJ Olaparib monotherapy Placebo IDFS R
(NCT02032823)
Veliparib
BROCADE [96] 2 ADV Veliparib + Placebo + PFS R
(NCT01506609) (Temozolomide) or CBDCA + PTX
(CBDCA + PTX)
(NCT02163694) [63] 3 ADV Veliparib + Placebo + PFS R
CBDCA + PTX CBDCA + PTX
Brightness [74] 3 NADJ (Veliparib + CBDCA) or
(Placebo + CBDCA) + Neoadjuvant CT
Placebo + Neoadjuvant CT pCR rate R
(NCT02032277)
Talazoparib
EMBRACA [61] 3 ADV Talazoparib monotherapy Physician’s choice CT PFS R
(NCT01945775)
ABRAZO [131] 2 ADV Talazoparib monotherapy Single arm study ORR R
(NCT02034916)
(NCT02282345) [75] 2 NADJ Talazoparib monotherapy Single arm study Safety R
Niraparib
BRAVO [60] 3 ADV Niraparib monotherapy Physician’s choice CT PFS R
(NCT01905592)
Rucaparib
(NCT00664781) [132] 2 ADV Rucaparib monotherapy Single arm study ORR, safety NR
(NCT01074970) [133] 2 ADJ Rucaparib + Cisplatin 2y-DFS NR
Cisplatin
ADJ Adjuvant, ADV Advanced, CBDCA Carboplatin, CT Chemotherapy, IDFS Interval disease-free survival, NADJ Neoadjuvant, NR Not yet recruiting, ORR Objective response
rate, PFS Progression-free survival, PTX Paclitaxel, R Recruiting, 2y-DFS 2-year disease-free survival
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therapy in BRCA-associated breast cancer is ongoing at
MD Anderson Cancer Center in Texas [75].
An interesting possibility for the future development of
PARP inhibition in BRCA-related breast cancers has been
raised by To et al. [76], who demonstrated a chemopre-
ventive effect of veliparib and olaparib in delaying mam-
mary tumor development in BRCA1-deficient mice. Data
in this field are still too limited to speculate whether these
findings could be translated to humans, but the concept
of a chemopreventive drug active in a population at high
risk of developing breast cancer is nonetheless intriguing.
The future of PARPi in prevention is not clear at this time
because of some chemotherapy-like toxic effects on bone
marrow, in particular [22].
Safety of PARPi
Toxicities of PARPi monotherapy appear to be similar to
cytotoxic chemotherapeutic agents. Data from prominentphase 1 and 2 studies are summarized in Table 5: the most
frequently reported adverse events in published studies
are grade 1–2 nausea, vomiting, diarrhea, fatigue, head-
ache, and anemia. The most common grade 3–4 toxicities
were nausea, vomiting, and hematological toxicity, with
anemia, lymphopenia, and thrombocytopenia being the
most common dose-limiting toxicities in dose-finding
studies [5, 34].
Conversely, dose-limiting toxicities observed in trials
of PARPi in combination with cytotoxic agents include
primarily hematologic toxicities [77, 78]. These potenti-
ated toxicities might restrict the future development of
some olaparib-cytotoxic combinations [79]. However,
using an intermittent schedule of PARPi administration
instead of continuous dosing has proved effective in
overcoming this limitation [23].
One major concern with drugs that inhibit DNA dam-
age repair mechanisms is the risk of development of new
primary malignancies. A small number of cases of
Table 5 Most common toxicities in studies of PARPi monotherapy in breast cancer patients
Compound Adverse event (range of occurrence across studies)
Grade 1–2 Grade 3–4
Olaparib [5–7, 34, 134] Nausea (32–58 %)
Fatigue (30–50 %)
Vomiting (11–34 %) Nausea (4–15 %)
Anorexia (12–27 %) Fatigue (5–15 %)
Anemia (5–25 %) Anemia (11–15 %)
Headache (22 %) Vomiting (4–11 %)
Diarrhea (11–18 %) Thrombocytopenia (3 %)
Taste alteration (13 %)
Veliparib [135] Dizziness (7 %) –
Nausea (7 %)
Dysgeusia (7 %)
Talazoparib [32] Fatigue (26 %)
Nausea (26 %)
Alopecia (grade 1 only, 26 %) Neutropenia (8 %)
Anemia (13 %) Thrombocytopenia (8 %)
Neutropenia (10 %) Anemia (5 %)
Flatulence (10 %)
Thrombocytopenia (3 %)
Niraparib [31] Anemia (48 %)
Nausea (42 %)
Thrombocytopenia (35 %) Thrombocytopenia (15 %)
Fatigue (34 %) Anemia (10 %)
Anorexia (25 %) Fatigue (8 %)










Grading according to Common Toxicology Criteria for Adverse Event
aGrade of reported adverse events not specified
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have been described in PARPi studies, with an incidence
of <1 % [22]. It is noteworthy that most patients had
already been treated with DNA-damaging classic chemo-
therapeutic drugs, which per se, represents a risk factor
for development of new malignancies. Nonetheless, the
increased concentration of gammaH2AX (a marker of
DNA damage [80–82]) in tissues of patients treated with
PARPi implies an accumulation of DSB in normaltissues and thus could lead to an increased risk of can-
cer secondary to DNA damage [22], warranting a high
level of attention when developing PARPi therapy, espe-
cially in the adjuvant setting.
Resistance to PARP inhibition
As with most targeted therapies, cancers develop resist-
ance to PARPi. All tumors that responded initially to
treatment with PARPi have ultimately progressed. So far,
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demonstrated, while two others have been hypothesized
[83–85] (Table 6). The first of the three established
mechanisms is the development of secondary mutations
that restore BRCA functionality. Preclinical and clinical
evidence indicates that genomic instability promoted by
PARPi in HR-deficient cells may result in secondary mu-
tations in the mutated BRCA1 or BRCA2 gene with res-
toration of functional protein expression and induction
of PARPi resistance [86–88]. The second mechanism in-
volves increased drug efflux with consequent reduction of
intracellular PARPi concentrations. PARP1 knock-out cells
show dramatic overexpression of P-glycoprotein [89];
PARP inhibition induces up-regulation of P-glycoprotein
expression in an in vivo mammary tumor model [59]. The
third mechanism of PARPi resistance is based on loss of
p53 binding protein 1 (53BP1). In vitro and in vivo experi-
ments showed that mutations causing loss of 53BP1 are
able to restore the HR in BRCA1/2 mutated cells, at least
partially [90–92]: this “DNA damage repair rewiring” ul-
timately leads to reduced sensitivity to PARPi [93].
Another hypothesized, but still unconfirmed, mechan-
ism of resistance to PARPi at the time of this submission
is the presence of BRCA1/2 forms with low level of ex-
pression, but that can be enhanced in the presence of
opportune stimuli (such as increase in DSB due to PARP
inhibition) – so called hypomorphic BRCA1/2 [84]. Fur-
thermore, the hypomorphs may lead to the reduced for-
mation of PARP-DNA complexes because of decreased
PARP expression (for example, by epigenetic silencing of
the gene or increased turnover of the protein) [85].
Some of the aforementioned mechanisms of resistance
are shared between PARPi and platinum compounds
[94], but the degree of overlap is not clear. For example,
Audeh et al. [43] reported response to olaparib in ovar-
ian cancer regardless of previous platinum sensitivity or
resistance, while in the basket trial by Kaufman et al. [6],
response rate to olaparib across breast cancer patients
showed a trend in favor of patients without prior plat-
inum exposure. However, platinum sensitivity can persist
after resistance to PARPi develops [95]. It is notable
that most of the ongoing studies of PARPi in advanced
breast cancer exclude patients who had been previously
treated with platinum compounds [61, 63, 96, 97] orTable 6 Mechanisms of resistance to PARP inhibitors
Mechanism of resistance Proposed explanation
Restoration of BRCA functionality Secondary mutation in BRC
DNA damage repair rewiring Mutations in p53 binding
Increased drug efflux Overexpression of P-glyco
Increased activity of BRCA1/2 proteins Increased stimulation of h
Decreased PARP expression Epigenetic silencing or inc
HR Homologous recombination. For further details refer to text and [83–85]who progressed on platinum-based chemotherapy regi-
mens [60, 62].
The existence of resistance mechanisms can limit the
clinical utility of PARPi; strategies to overcome acquired
resistance are needed. For example, it has been shown
that drugs able to block efflux pumps may revert their
PARPi resistance [59]. Further, when PARPi resistance is
due to restoration of BRCA-proficiency, induction of a
BRCAness phenotype via CDK1 inhibition may render
the tumor cells again susceptible to PARPi [98].
Predicting response to PARPi
No established biomarker of response to PARPi is cur-
rently available. A candidate biomarker is the homolo-
gous recombination deficiency (HRD) score, which
combines three different DNA-based metrics of genomic
instability that are highly associated with BRCA1/2 mu-
tational status or predictive of sensitivity to platinum
chemotherapy [99]; Richardson et al. [100] demonstrated
that the HRD score is able to identify patients with
breast tumors with underlying HR deficiency (including
BRCA1/2 non-mutated tumors) that benefit from neoad-
juvant platinum therapy. In PrECOG 0105, high HRD
scores identified patients with a higher likelihood of
achieving pathological complete response to platinum-
based neoadjuvant chemotherapy [101]. However, data
from the GeparSixto study showed a statistically signifi-
cant increase in pathological complete response rates in
patients with high HRD score; the benefit was observed
irrespective of BRCA1/2 status (mutated versus intact)
[102]. These results could not be replicated in the ad-
vanced setting, although the fact that the HRD assay was
performed on primary tumor specimens rather than
metastatic samples may have limited its ability to predict
responsiveness to carboplatin in metastatic breast can-
cers (TNT trial) [103]. The value of HRD score in pre-
dicting response to therapy is being prospectively tested
in both neoadjuvant and advanced settings using plat-
inum compounds [104] and PARPi [97, 105], respect-
ively. Other promising biomarkers are the assessment of
PARP activity through measurement of poly(ADP-ri-
bose) levels [93, 106], the evaluation of HR proficiency
through the formation of nuclear RAD51 foci [107, 108],




ypomorphic BRCA1/2 protein expression Partial
reased turnover None
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ation of levels of 53BP1 expression [17, 93].
Strategies to expand PARPi application to BRCA-proficient
breast cancers
Theoretically, PARPi activity could be expanded to breast
cancers without BRCA1/2 mutations; several preclinical
experiments support this possibility by focusing on the
impairment of the HR pathway. PTEN [110] and ATM
[111, 112] deficiencies correlate with sensitivity to PARPi
both in vitro and in vivo; moreover, CDK1 inhibition [98]
and histone deacetylase inhibition [113] have been shown
to efficiently sensitize BRCA-proficient cells to PARPi
in vitro and, in animal models, in vivo. A phase 1 study is
ongoing in patients with solid tumors testing the associ-
ation of veliparib, a selective CDK inhibitor (dinaciclib)
and carboplatin: an expanded cohort of BRCA-proficient
tumors is planned [114]. Unfortunately, no validated bio-
marker of HR dysfunction other than germline BRCA1/2
mutations is currently available.
Alterations in the HR pathway different from BRCA1/
2 mutations may determine an HR-deficient phenotype
similar to BRCA-deficient tumor (namely, BRCAness)
[20]. Such alterations include BRCA1/2 suppression (for
example, by promoter methylation) or mutations in
genes encoding other proteins involved in HR (such as
PTEN, FANCF, RAD51, ATM, and CDK1) [20, 28, 110].
In line with this hypothesis, talazoparib will be tested in
BRCA1/2 wild type breast cancer with high HRD score
or deleterious germline or somatic mutation implicated
in the HR pathway [97].
Other options to exploit PARP inhibition in BRCA-
proficient breast cancers currently under investigation
(mainly in cell lines and animal models, but also in clin-
ical trials) include PI3K inhibition [115, 116] and TGFβ
activation [117]. Preliminary positive data of clinical effi-
cacy of PARPi/PI3K inhibitors in BRCA wild type ovar-
ian and breast cancer have been presented by Matulonis
et al. [118] at the 2015 American Association for Cancer
Research Annual Meeting.
Conclusions
PARP inhibition is a promising strategy for the treatment
of breast cancer associated with germline BRCA1/2 muta-
tions and papillary serous ovarian cancers. Efficacy data
from phase 1 and 2 studies showed encouraging objective
response rates with acceptable toxicity profiles for PARPi
monotherapy. The initial data are consistent with those of
other targeted therapies in identifiable subsets of tumors.
There is great excitement about the ongoing phase 3 trials
in the metastatic, adjuvant, and neoadjuvant settings.
However, other questions apart from clinical efficacy
need to be addressed before PARPi will become part of
clinical practice. For example, the long-term effects ofcontinuous administration of this class of drugs are not
yet fully characterized: will prolonged exposure to PARPi
confer increased risk of hematological toxicity or devel-
opment of new primary malignancies? This is a concern
of particular importance in the adjuvant setting. Increas-
ing use of platinum in early triple-negative disease may
influence the way PARPi are used given the overlapping
mechanisms of action and resistance.
New strategies are being examined to expand the ap-
plication of PARPi in BRCA-associated cancers beyond
breast and ovarian, and in some sporadic tumors. PARPi
should be more fully studied in ER-positive BRCA-
associated tumors as well. PARPi appear likely to assume
an important role in the management of patients with
BRCA-associated tumors, and possibly in other carefully
defined tumor subsets as well.
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